

04. Correlation of Radiographic Damage and Metabolic Syndrome in Spondyloarthritis A Cross-Sectional Study

by Hendra Gunawan

Submission date: 15-Aug-2022 02:54PM (UTC+0800)

Submission ID: 1882682690

File name: abolic_Syndrome_in_Spondyloarthritis_A_Cross-Sectional_Study.pdf (629.85K)

Word count: 4629

Character count: 25897

CORRELATION OF RADIOGRAPHIC DAMAGE AND METABOLIC SYNDROME IN SPONDYLOARTHRITIS: A CROSS-SECTIONAL STUDY

HENDRA GUNAWAN^{1*}, SONY WIBISONO MUDJANARKO², AWALIA³, LITA DIAH RAHMAWATI³,
JOEWONO SOEROSO³, AGUNG PRANOTO²

¹Department of Residence of Internal Medicine, Dr. Soetomo General Hospital Surabaya – Airlangga University, Indonesia. ²Department of Internal Medicine – Endocrinology, Metabolic, and Diabetes Division, Dr. Soetomo General Hospital, Surabaya, Indonesia – Airlangga University, Indonesia. ³Department of Internal Medicine – Rheumatology Division, Dr. Soetomo General Hospital, Surabaya, Indonesia – Airlangga University, Indonesia. Email: Sylvester.gunawan@gmail.com/Awalia_nov74@yahoo.com

Received: 08 August 2019, Revised and Accepted: 08 August 2019

ABSTRACT

Background: Cardiovascular complication remains the long-term complications in spondyloarthritis (SpA). Previous studies revealed that metabolic syndrome is the risk factor of cardiovascular in SpA patients. Previous studies also revealed that the prevalence of the metabolic syndrome is 34.9-45.7% in SpA patients. However, previous studies also revealed the controversy of the correlation of SpA' disease activity with metabolic syndrome.

Aim: The aim of the study was to investigate the correlation of SpA' radiographical damage measured with a modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) score with metabolic syndrome in SpA patients, which routinely visited Rheumatology Outpatient Department in Dr. Soetomo General Hospital.

Methods: An observational study with cross-sectional design with consecutive sampling technique was conducted in July–October 2018. All SpA patients who fulfilled the inclusion criteria were included in this study. Data analysis was performed with SPSS v21.0.

Results: There were 33 SpA patients (10 males and 23 females) included in this study. The average age was 48.18±12.27 years-old. The average mSASSS score was 24.36 (K:0.93, p:0.00). Metabolic syndrome was diagnosed in 54.5% patients with 100% patients had central obesity, 66.7% had increased blood pressure, 61.5% had impaired fasting glucose, 55.6% had increased triglycerides, and 77.8% had decreased high-density lipoprotein cholesterol. Positive correlation between mSASSS score and metabolic syndrome was observed (r:0.510, p:0.002).

Conclusion: A correlation between SpA disease activity measured with mSASSS score and metabolic syndrome was observed. Therefore, routine metabolic syndrome screening is strongly suggested for SpA patients.

Keywords: Metabolic syndrome, Spondyloarthritis, Modified stoke ankylosing spondylitis spinal score.

© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>) DOI: <http://dx.doi.org/10.22159/ijap.2019.v11s5.T0049>

61 BACKGROUND

Spondyloarthritis (SpA) is a chronic inflammatory disorder which is related to the presence of HLA-B27. SpA has various clinical symptoms ranging from chronic inflammatory back pain, peripheral arthritis, to enteropathy arthritis, and uveitis [1,2]. Among its long-term complication, cardiovascular complications remain the leading morbidity and mortality in SpA patients. Previous studies revealed that cardiovascular complications risk such as myocardial infarction and cerebrovascular accident are accelerated in SpA population [3,4].

One of the cardiovascular risk factors is metabolic syndrome. It is a constellation of obesity, insulin resistance, hypertension, and dyslipidemia [5]. Mottillo *et al.* revealed that metabolic syndrome increases the risk of cardiovascular complications at least two-fold and all-cause mortality by at least 1.5-fold. Previous studies also revealed that the prevalence of the metabolic syndrome is increased in SpA patients, ranging from 34.9% to 45.7% [6,7]. Interestingly, current understandings of metabolic syndrome have suggested that metabolic syndrome is associated with chronic low-grade inflammation [8]. The mechanism remains uncertain, but it involves proinflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interleukin (IL)-6 which contributes to the insulin resistance, central obesity, dyslipidemia, and hypertension [8,9].

Despite the increased prevalence in rheumatic diseases, few studies have reported the correlation of SpA' disease activity and functional

score to metabolic syndrome with various outcomes [6,7,10-12]. However, as SpA' disease activity score such as bath-AS ankylosing spondylitis disease activity index (BASDAI) is dependent to subject's psychological and functional state, it may not reflect the severity of SpA [13,14]. Radiographic assessment can be used to assess the severity of SpA using modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) [15]. Furthermore, assessing radiographic damage can evaluate therapy response, the progression of the disease, and associated with magnetic resonance imaging [16]. This study aimed to investigate the correlation of radiographic damage, measured with mSASSS score with metabolic syndrome in SpA patients.

METHODS

This study is a cross-sectional study conducted from July 2018 to October 2018 in Rheumatology Outpatient installation Dr. Soetomo General Hospital Surabaya, an A class hospital with consecutive sampling technique to recruit the subject. This study has been approved by the Ethics Committee of Dr. Soetomo General Hospital on July 10, 2018, with reference number: 0385/KEPK/VII/2018.

Study population

Consecutive patients (n=33; 10 males and 23 females; mean age 48.18±12.27 years) attending the Rheumatology Outpatient Department of Dr. Soetomo General Hospital Surabaya between July 2018 and September 2018, were enrolled in the study. All patients fulfilled the ASAS 2010 criteria for SpA [1]. The exclusion criteria in

this study are smoking, previous alcohol consumption, chronic kidney disease, previous medications (glucocorticoid and anti-TNF α), history of malignancy, infection (HIV and hepatitis), and other autoimmune diseases. The median of disease duration was 4 years (0–43 years) and six patients were diagnosed with SpA at the time of the recruitment. Nineteen patients were taking sulfasalazine with median dose 1000 mg/day (500–2000 mg/day) and eight patients were taking methotrexate with median dose 10 mg/week (7.5–10 mg/weekly). Fourteen patients were taking Anti-hypertensive drugs (angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker, calcium channel blocker, β -blocker, or combination therapy), 19 patients were taking dyslipidemia drugs (statins or fibrates), and four patients were taking oral hypoglycemic agents (biguanides).

mSASSS score

Radiography assessment was measured using mSASSS score. There are two components which are evaluated in mSASSS score, the anterior vertebrae which consist of the lower border of C2 to the upper border of Th1 and the lumbar vertebrae which consist of the lower border of Th12 to the upper border of S1 combined to 24 vertebrae segments at a lateral view. The vertebrae segments were evaluated for the presence of erosion and/or sclerosis and/or squaring (1 point), syndesmophyte (2 points), and bridging syndesmophytes (three points). The total score ranges from 0 to 72 [15]. The radiology assessment was performed by two rheumatologists (Awalia and Lita Diah) who were blinded to demographic and clinical manifestations. Both readers scored the radiography assessment at the same time and registered the changes of vertebrae segments separately; therefore, both scores could be computed.

Metabolic syndrome

Metabolic syndrome was assessed with National Cholesterol Education Program-Adult Treatment Panel (NCEP)-ATP III criteria. According to NCEP-ATP III, metabolic syndrome is defined as the presence of minimal three of the following five risk factors such as (1) central obesity, (2) elevated triglycerides (>150 mg/dL) or previous dyslipidemia medication, (3) fasting glucose >100 mg/dL or previous diabetes medication, (4) blood pressure >130/80 mmHg, and (5) high-density lipoprotein (HDL) <40 mg/dL for male and <50 mg/dL for female [17]. As for central obesity, we used the modified criteria of central obesity based on waist circumference >90 cm for male and >80 cm for female or body mass index for Indonesian populations which defines overweight at 23.0–24.9 kg/m², obese I at 25.0–29.9 kg/m², and obese II at \geq 30 kg/m² [18,19].

Statistical analysis

The statistical analysis was made by SPSS v21.0 software for MacOSX. Interobserver analysis of mSASSS score to validate the mSASSS score was performed with Cohen-Kappa analysis. Shapiro-Wilk test was used to test the normality of the mSASSS score, followed with Mann-Whitney U-test for mean differences of mSASSS score based on the presence of the metabolic syndrome. Spearman's rank correlation was used for correlation analysis between mSASSS score and metabolic syndrome and the number of metabolic syndrome component.

RESULTS

Demography

There were 33 SpA patients who visited the rheumatology outpatient department from July to October 2018 consisted of 23 females and 10 males. There were 6 (18.1%) newly diagnosed SpA patients; therefore, 27 patients had a history of conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs), with 8 patients (24.2%) on methotrexate, and 19 patients (57.6%) on sulfasalazine. No patients had a history of metabolic syndrome before diagnosed with SpA, smoking, alcohol consumption, chronic kidney disease, or anti-TNF α medication. Table 1 shows the basic characteristics of the subjects.

Prevalence of metabolic syndrome components in SpA patients

Fig 1 shows the prevalence of each component of metabolic syndrome in SpA patients. Central obesity was the most frequent metabolic

Table 1: Basic characteristics of the study

Parameter	Value
Age (years)	50 (22–72)
Waist circumference (cm)	88 (68–108)
Body Mass Index (kg/m ²)	26.45 (17.48–36.07)
Blood pressure	
Systolic (mmHg)	120 (100–170)
Diastolic (mmHg)	80 (70–90)
Hemoglobin (g/dL)	12.7 (9.3–15.9)
Leukocytes (μ /L)	7910 (3490–14450)
Platelets (μ /L)	326,000 (206,000–555,000)
Fasting glucose concentration (mg/dL)	97 (78–284)
Total cholesterol (mg/dL)	194 (115–255)
Triglycerides (mg/dL)	115 (45–372)
HDL-cholesterol (mg/dL)	47 (31–99)
LDL-cholesterol (mg/dL)	118 (46–157)
Duration of disease (years)	4 (1–43)
mSASSS score	23 (9–60)
On anti-hypertensive (%)	14 (42)
On statins (%)	14 (42)
On oral antidiabetic drugs (%)	4 (12)

mSASSS: Modified stoke ankylosing spondylitis spinal score




Fig. 1: Prevalence of the metabolic syndrome components in spondyloarthritis patients

syndrome component found in this study with a prevalence of 67%, followed with decreased HDL-cholesterol and impaired glucose tolerance. When we classified the patients with central obesity according to their body mass index (BMI) for Indonesian populations, we found that 92% met the obese criteria (10 with obese I and 10 with obese II) and 8% (two patients) met the overweight criteria.

About 42% (14 patients) of the patients met the criteria of elevated blood pressure or had an antihypertensive drugs history before. When we classified patients with elevated blood pressure according to their blood pressure with JNC VII criteria, we found that 42% (6 out of 14) met the criteria of hypertension Stage I, 29% (4 out of 14) met the criteria of hypertension Stage II, and 29% (4 out of 14) had a normal blood pressure.

The prevalence of impaired glucose tolerance was 46% (15 patients) in this study, with 27% (4 out of 15) had already been diagnosed with type 2 diabetes mellitus. All patients with diabetes received oral antidiabetic drugs (biguanides).

The prevalence of elevated triglycerides was 42% (14 patients) in this study. All patients with elevated triglycerides were on statins. When we classified the patients according to their triglycerides level with NCEP-ATP III classification, we found that 43% (6 out of 14) were on borderline-high triglycerides (150–199 mg/dL), 43% (6 out of 14) were on high triglycerides (200–499 mg/dL), and 14% (2 out of 14) were on normal triglycerides level.

The prevalence of decreased HDL-cholesterol was 58% (19 patients) in this study with 73.7% (14 out of 19) were on statins. When we classified the patients according to their HDL-cholesterol level with NCEP-ATP

III classification, we found that 47% (9 out of 19) were on low level (<40 mg/dL), 47% (9 out of 19) were on normal level, and 6% (1 out of 19) were on a high level of HDL-cholesterol (>60 mg/dL).

Prevalence of metabolic syndrome in SpA patients

The prevalence of metabolic syndrome in this study was 54.5% (18 out of 33 patients) according to the NCEP-ATP III classification of metabolic syndrome modified for Indonesian populations. When we split the patients based on metabolic syndrome diagnosis, we found that 44.4% (8 out of 18) had three components of metabolic syndrome, 38.9% (7 out of 18) had four components of metabolic syndrome, and 16.7% (3 out of 18) had five components of metabolic syndrome as shown in Fig. 2.

Table 2 describes the metabolic syndrome parameters in SpA patients according to the presence of the metabolic syndrome. When we classified the patients according to the presence of metabolic syndrome, we found that patients with metabolic syndrome were significantly older ($p=0.003$) and had a longer duration of diseases ($p=0.000$). All patients with metabolic syndrome had central obesity (100%), had a significantly greater waist circumference ($p=0.002$), and BMI ($p=0.000$) compared with patients without metabolic syndrome.




Fig. 2: The distribution of metabolic syndrome components according to metabolic syndrome

Table 2: Characteristic of spondyloarthritis patients according to the presence of the metabolic syndrome

Parameter	Metabolic syndrome		p
	Yes (n=18)	No (n=15)	
Sex			
Male (%)	4 (22.2)	6 (40)	0.003*
Female (%)	14 (77.8)	9 (60)	
Age (years)	52 (39-72)	44 (22-63)	
Central obesity (%)	18 (100)	4 (26.7)	0.002*
Waist circumference (cm)	91.5 (82-108)	77 (68-106)	0.000*
Body mass index (kg/m ²)	30.06 (23.63-36.07)	21.63 (17.48-31.25)	
Elevated blood pressure (%)	12 (66.67)	2 (13.3)	0.213
Systolic (mmHg)	135 (100-170)	120 (110-160)	0.185
Diastolic (mmHg)	80 (70-90)	80 (70-90)	
Impaired glucose tolerance (%)	11 (61.5)	2 (13.3)	0.001*
Fasting glucose concentration (mg/dL)	103 (86-284)	93 (78-103)	
Increased triglycerides (%)	10 (55.6)	4 (26.7)	0.093
Triglycerides (mg/dL)	142.5 (60-372)	104 (45-203)	
Decreased HDL-cholesterol (%)	14 (77.8)	5 (33.3)	0.128
HDL-cholesterol (mg/dL)	46 (31-57)	50 (32-99)	
Duration of disease (years)	7.5 (1-43)	2.25 (1.25-7.25)	0.000*
mSASSS score	26 (18-60)	20 (9-29)	0.004*

*Significant with Mann-Whitney U-test analysis ($p<0.05$). mSASSS: Modified stoke ankylosing spondylitis spinal score

Elevated blood pressure was observed in 66.67% (12) patients with metabolic syndrome; however, there were no significant differences in systolic and diastolic blood pressure in patients with and without metabolic syndrome ($p=0.213$ and $p=0.185$, respectively).

Impaired glucose tolerance was more prevalent in patients with metabolic syndrome (61.5%) compared to those without metabolic syndrome (13.3%). When we compared the fasting glucose concentration, we found a higher glucose concentration in patients with metabolic syndrome than those without metabolic syndrome ($p=0.000$).

Increased triglycerides were observed in 61.5% (11) patients with metabolic syndrome, compared to 26.7% (4) in patients without metabolic syndrome. There were no significant differences in triglycerides level in patients with and without metabolic syndrome ($p=0.093$). Similarly, the prevalence of decreased HDL-cholesterol was higher in patients with metabolic syndrome (77.8%) compared to patients without metabolic syndrome (33.3%). There were no differences in HDL-cholesterol levels in patients with or without metabolic syndrome ($p=0.128$).

mSASSS score

The median score of mSASSS score in this study was 23, as shown in Table 1 with interobserver agreement calculated with Cohen-Kappa's method $\kappa=0.93$, $p=0.00$. When we compared the mSASSS score according to the presence of metabolic syndrome, we found that patients with metabolic syndrome had higher mSASSS score compared to those without metabolic syndrome ($p=0.004$).

Correlation of mSASSS score and metabolic syndrome in SpA patients

Correlation of mSASSS score and metabolic syndrome was calculated with Spearman correlations. We found a moderate correlation between mSASSS score and metabolic syndrome ($p=0.510$, $p=0.002$). We also found a weak correlation between mSASSS score and the number of metabolic syndrome components ($p=0.448$, $p=0.009$).

DISCUSSION

SpA is a chronic inflammatory disease with various clinical manifestations, ranging from ankylosing spondylitis to undifferentiated arthritis. It affects male predominantly with male: female ratio 2-3:1 [20]. However, female was more predominant in this study, accounts for 67% subjects in this study with an average age 48 years old. This supports the previous study which reported that the male: female ratio

is equal in older populations (45 years old) and female was associated with lower quality of life and more functional limitations despite lower degrees of radiographical damage [21,22]. The reason female was predominant in this study because our study location is referral hospital. Thereby, our cases were difficult cases which is commonly found in female with as (Skare *et al.*, 2012).

The prevalence of metabolic syndrome in this study was 54.5%, which was higher compared to the prevalence of metabolic syndrome in a healthy population that visited primary health care in Jakarta, which was 28.4% [23]. This finding supports previous studies which reported that the prevalence of metabolic syndrome in SpA populations is higher than the healthy population [3,24]. Compared to other studies, Malesci *et al.* reported that the prevalence of metabolic syndrome in SpA patients in Italy was 45.8% [6]. Maia *et al.*, which observed metabolic syndrome in Brazilian ankylosing spondylitis patients and Papadakis *et al.*, which observed metabolic syndrome in male Greek ankylosing spondylitis patients reported that the prevalence of metabolic syndrome was 27% and 34.9%, respectively [7,11]. The differences between this study and previous studies might be due to treatment differences because all of the patients in this study received csDMARDs which did not affect metabolic syndrome's parameters directly like anti-TNF α which was used in some of the previous studies [25].

Analyzing the component of metabolic syndrome, central obesity was the most common metabolic syndrome's component found in this study, followed by decreased HDL-cholesterol and impaired glucose tolerance. These findings are different from previous studies since elevated blood pressure was the more prevalent metabolic syndrome's component. This might be due to the predominant gender differences in our study in which female was the more predominant, with average age 48 years, and 69.6% of the female were in the menopause period. Menopause is associated with hyperandrogenemia which associated with insulin resistance and abdominal fat disposition [26].

When we analyzed the patients according to the presence of metabolic syndrome, we found that central obesity was still the most prevalent metabolic syndrome component in SpA patients with metabolic syndrome followed by decreased HDL-cholesterol, elevated blood pressure, and impaired glucose tolerance. These findings support previous studies which reported that SpA patients with metabolic syndrome were older and had more cardiovascular comorbidities than those who did not have metabolic syndrome [7,11]. Because all patients in this study were not on anti-TNF α , we thought that chronic inflammation due to TNF- α activation might have a part in the adverse metabolic parameter in this study [9,24].

To the best of our knowledge, this is the first study which observed the mSASSS score in Indonesian population. The average mSASSS score in this study was higher than the previous studies indicated that there was more radiographical damage in our patients [15,27]. This might be due to the nature of SpA, which is chronic progressive and patient's characteristics in this study. All patients in this study were referral cases, so the possibility of late referral cases needed to be accounted [28]. When we analyzed the mSASSS score based on metabolic syndrome, we found that the average mSASSS score in patients with metabolic syndrome was significantly higher than those who did not have metabolic syndrome. This finding is the first one who observed mSASSS score in patients with metabolic syndrome. This supports the hypothesis that inflammation in the entheses would increase the activation of IL-17, which further activates the IL-23/IL-17 axis [29]. Golden *et al.* reported that activation of IL-23/IL-17 axis in entheses would not only affect local inflammation but also associated with extra-articular complications of SpA [30].

This is the first study which observed the positive correlation of mSASSS score and metabolic syndrome and number of metabolic syndrome components in SpA patients. These findings supported the findings of Papadakis *et al.*, in male Greek ankylosing spondylitis patients

and Alonso-Blanco Morales *et al.*, in Spanish ankylosing spondylitis patients [7,10]. However, previous studies used other methods such as BASDAI and BASFI in which both methods evaluate disease activity from the patient's perception of their disease [31,32]. Thus, we thought that the severity of inflammation evaluated with mSASSS score was more objective to evaluate the duration of long-term inflammation in SpA; however, further studies are needed to evaluate the relationships between mSASSS score and long-term complication of SpA.

This study has some limitations. We analyzed small numbers of patients with cross-sectional design in relatively limited time; therefore, the cause-effect relationships between chronic inflammation in SpA and metabolic syndrome could not be determined. The location of this study is in A class hospital; therefore, all patients were referral cases, and it could affect the higher mSASSS score in this study.

CONCLUSION

Our findings showed that the greater prevalence of metabolic syndrome in chronic inflammatory diseases, in this case, was SpA. The correlation of radiographical damage evaluated by mSASSS score with metabolic syndrome and number of metabolic syndrome components suggested the role of inflammation to the pathogenesis of metabolic syndrome in SpA patients. Early diagnosis and treatment of metabolic syndrome in SpA patients are needed to prevent cardiovascular complications.

ACKNOWLEDGMENT

We acknowledge Poernomo Boedi Setiawan, dr. Sp.PD-KGEH as the head of Internal Medicine Department of Airlangga University for giving us permission to manage and write this case report. We also acknowledge all staffs in Internal Medicine Department for the support given to us.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this article.

REFERENCES

- Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, *et al.* The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011;70:25-31.
- Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. *Rheumatology (Oxford)* 2005;44:1483-91.
- Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: A systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2011;63:557-63.
- Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: An updated meta-analysis. *Semin Arthritis Rheum* 2015;44:551-5.
- Reaven G. The metabolic syndrome: Is this diagnosis necessary? *Am J Clin Nutr* 2006;83:1237-47.
- Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G, *et al.* High prevalence of metabolic syndrome in patients with ankylosing spondylitis. *Clin Rheumatol* 2007;26:710-4.
- Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, *et al.* High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF α treatment: Correlation with disease activity. *Clin Exp Rheumatol* 2009;27:292-8.
- Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. *Mediators Inflamm* 2010;2010:???
- Jung UJ, Choi MS. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 2014;15:6184-223.
- Blanco-Morales EA, Bravo-Ferrer J, Rey R, Bejerano C, Fernandez C, Oreiro N, *et al.* FRI0208 metabolic syndrome in spondyloarthritis. Prevalence and associated factors. *Ann Rheumatic Dis* 2015;2015:499-500.
- Maia DG, Augusto KL, Bezerra MC, Rodrigues CEM. Metabolic

- syndrome in patients with ankylosing spondylitis receiving anti-TNF α therapy: Association with predictors of cardiovascular risk. *Clin Rheumatol* 2017;36:2371-6.
12. Betancur G, Orozco MC, Schneeberger E, Lizarraga A, Zamora N, Sommerfleck FA, et al. Prevalence of obesity and metabolic syndrome in patients with axial spondyloarthritis. *Arthritis Rheumatol* 2015;67 Suppl 10.
 13. Altan L, Sivrioglu Y, Ercan I. Can bath ankylosing spondylitis disease activity index be affected by accompanying fibromyalgia or depression? *Arch Rheumatol* 2015;30:34-9.
 14. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF α inhibitors. *Ann Rheum Dis* 2011;70:1375-81.
 15. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL, et al. Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. *Ann Rheum Dis* 2005;64:127-9.
 16. Ibrahim A, Gladman DD, Thavaneswaran A, Eder L, Helliwell P, Cook RJ, et al. Sensitivity and specificity of radiographic scoring instruments for detecting change in axial psoriatic arthritis. *Arthritis Care Res (Hoboken)* 2017;69:1700-5.
 17. National cholesterol education program. Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *Circulation* 2001;202:3143-421.
 18. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to asians? *Diabetes Care* 2004;27:1182-6.
 19. Tjokroprawiro A, Wibisono S. Guloh-sisar: Sepuluh Petunjuk Pola Hidup Sehat. Seminar Untuk Dokter Anak Cabang Jawa Timur. Vol. 29. Surabaya: Practical Guidelines fro Healthy Daily Life; 2014.
 20. Harper BE, Reveille JD. Spondyloarthritis: Clinical suspicion, diagnosis, and sports. *Curr Sports Med Rep* 2009;8:29-34.
 21. Haroon NN, Paterson JM, Li P, Haroon N. Increasing proportion of female patients with ankylosing spondylitis: A population-based study of trends in the incidence and prevalence of AS. *BMJ Open* 2014;4:e006634.
 22. Neuenschwander R, Ciurea A. Gender differences in axial spondyloarthritis. *World J Rheumatol* 2014;4:35-43.
 23. Soewondo P, Purnamasari D, Oemardi M, Waspadji S, Soegondo S. Prevalence of metabolic syndrome using NCEP/ATP III criteria in jakarta, indonesia: The jakarta primary non-communicable disease risk factors surveillance 2006. *Acta Med Indones* 2010;42:199-203.
 24. Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, et al. Cardiovascular risk profile in patients with spondyloarthritis. *Joint Bone Spine* 2014;81:57-63.
 25. Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients preliminary report. *Postepy Dermatol Alergol* 2018;35:53-9.
 26. Kozakowski J, Gietka-Czernel M, Leszczyńska D, Majos A. Obesity in menopause our negligence or an unfortunate inevitability? *Prz Menopauzalny* 2017;16:61-5.
 27. Ramiro S, van Tubergen A, Stolwijk C, Landewé R, van de Bosch F, Dougados M, et al. Scoring radiographic progression in ankylosing spondylitis: Should we use the modified stoke ankylosing spondylitis spine score (mSASSS) or the radiographic ankylosing spondylitis spinal score (RASSS)? *Arthritis Res Ther* 2013;15:R14.
 28. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20:S16-22.
 29. Raychaudhuri SP, Raychaudhuri SK. IL-23/IL-17 axis in spondyloarthritis-bench to bedside. *Clin Rheumatol* 2016;35:1437-41.
 30. Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities. *Cytokine* 2013;62:195-201.
 31. Aliling J, Brent IH. Criteria and disease activity measures in axial spondyloarthropathies. *Clin Adv Spondylitis* 2016;2:2-38.
 32. Braun J, Kiltz U, Baraliakos X, van der Heijde D. Optimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis. *Clin Exp Rheumatol* 2014;32:S-96-104.

04. Correlation of Radiographic Damage and Metabolic Syndrome in Spondyloarthritis A Cross-Sectional Study

ORIGINALITY REPORT

17%

SIMILARITY INDEX

12%

INTERNET SOURCES

15%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

1	www.jraas.com Internet Source	1%
2	Hamid Jan B. Jan Mohamed, Amal K. Mitra, Laila Ruwaida Mohd Zainuddin, Soo Kah Leng, Wan Manan Wan Muda. "Women Are at a Higher Risk of Metabolic Syndrome in Rural Malaysia", Women & Health, 2013 Publication	1%
3	www.hindawi.com Internet Source	1%
4	Www.dovepress.com Internet Source	<1%
5	journals.lww.com Internet Source	<1%
6	repository-tnmgrmu.ac.in Internet Source	<1%
7	M. Fukui. "Metabolic syndrome is not associated with markers of subclinical atherosclerosis, serum adiponectin and	<1%

endogenous androgen concentrations in Japanese men with Type 2 diabetes", *Diabetic Medicine*, 8/2007

Publication

8

Diana Gavrilă, Diego Salmerón, José-Manuel Egea-Caparrós, José M Huerta et al.

"Prevalence of metabolic syndrome in Murcia Region, a southern European Mediterranean area with low cardiovascular risk and high obesity", *BMC Public Health*, 2011

Publication

<1 %

9

Ozlem Equils, Sapna Singh, Semra Karaburun, Daning Lu, Manikkavasagar Thamocharan, Sherin U. Devaskar. "Intra-uterine Growth Restriction Downregulates the Hepatic Toll Like Receptor-4 Expression and Function", *Clinical and Developmental Immunology*, 2005

Publication

<1 %

10

doczz.net

Internet Source

<1 %

11

Oh, S.Y.. "The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease", *Metabolism*, 2006

Publication

<1 %

12

Jibrān Suāleh Muhammad, Muhammad Ishaq Ghauri. "Clinical patterns of seronegative spondyloarthropathies in a tertiary centre in

<1 %

13

journalarticle.ukm.my

Internet Source

<1 %

14

www.freepatentsonline.com

Internet Source

<1 %

15

www.omicsonline.org

Internet Source

<1 %

16

Kyu-Hyouck Kyoung, Sung-Gyu Lee, Shin Hwang, Ki-Hun Kim, Suk-Kyung Hong. "Liver Steatosis in Brain-Dead Donors: Progression Pattern and Affecting Factors",
Transplantation Proceedings, 2020

Publication

<1 %

17

Praveena Chiowchanwisawakit. "Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis", Arthritis & Rheumatism, 08/2011

Publication

<1 %

18

Yokoyama, H.. "Relationship between metabolic syndrome components and vascular properties in Japanese type 2 diabetic patients without cardiovascular disease or nephropathy", Diabetes Research and Clinical Practice, 200702

Publication

<1 %

19

dmsjournal.biomedcentral.com

Internet Source

<1 %

20

e-nrp.org

Internet Source

<1 %

21

A Wanders. "Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?", *Annals of the Rheumatic Diseases*, 2005

Publication

<1 %

22

P Kontunen, K Vuolteenaho, R Nieminen, L Lehtimäki, H Kautiainen, YA Kesäniemi, O Ukkola, M Kauppi, M Hakala, E Moilanen. "Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis", *Scandinavian Journal of Rheumatology*, 2011

Publication

<1 %

23

Siebuhr, Anne S, Yi He, Natasja S Gudmann, Aurelie Gram, Cecilie F Kjelgaard-Petersen, Per Qvist, Morten A Karsdal, and Anne C Bay-Jensen. "Biomarkers of cartilage and surrounding joint tissue", *Biomarkers in Medicine*, 2014.

Publication

<1 %

24	WWW.MDPI.COM Internet Source	<1 %
25	onlinelibrary.wiley.com Internet Source	<1 %
26	repository.ubn.ru.nl Internet Source	<1 %
27	www.ncbi.nlm.nih.gov Internet Source	<1 %
28	Anoek de Koning, Freek de Bruin, Rosaline van den Berg, Sofia Ramiro et al. "Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort", <i>Annals of the Rheumatic Diseases</i> , 2018 Publication	<1 %
29	K Shiwaku. "Overweight Japanese with body mass indexes of 23.0–24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians", <i>International Journal of Obesity</i> , 01/2004 Publication	<1 %
30	biomedpharmajournal.org Internet Source	<1 %
31	bmcmusculoskeletdisord.biomedcentral.com Internet Source	<1 %

32	eje.bioscientifica.com Internet Source	<1 %
33	juri.urologi.or.id Internet Source	<1 %
34	translational-medicine.biomedcentral.com Internet Source	<1 %
35	wnoziz.up.poznan.pl Internet Source	<1 %
36	www.acarindex.com Internet Source	<1 %
37	www.globalscienceresearchjournals.org Internet Source	<1 %
38	www.karger.com Internet Source	<1 %
39	Chengappa G. Kavadichanda, Jie Geng, Sree Nethra Bulusu, Vir Singh Negi, Malini Raghavan. "Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B*27 Connection", <i>Frontiers in Immunology</i> , 2021 Publication	<1 %
40	Denis Poddubnyy, Deepak R. Jadon, Filip Van den Bosch, Philip J. Mease, Dafna D. Gladman. "Axial involvement in psoriatic arthritis: an update for rheumatologists", <i>Seminars in Arthritis and Rheumatism</i> , 2021 Publication	<1 %

41

Gerlinde Layh-Schmitt. "The interleukin-23/interleukin-17 axis in spondyloarthritis", *Current Opinion in Rheumatology*, 07/2008

Publication

<1 %

42

Madan, A.K.. "Metabolic syndrome: yet another co-morbidity gastric bypass helps cure", *Surgery for Obesity and Related Diseases*, 200601/02

Publication

<1 %

43

Muharrem Geçene, Figen Tuncay, Pınar Borman, Dogan Yücel, Mehmet Senes, Behice Kaniye Yılmaz. "Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels", *Rheumatology International*, 2012

Publication

<1 %

44

Uta Kiltz, Xenofon Baraliakos, Pantelis Karakostas, Manfred Igelmann et al. "Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?", *Arthritis Care & Research*, 2012

Publication

<1 %

45

Xiaoping Weng. "An urban-rural comparison of the prevalence of the metabolic syndrome

<1 %

in Eastern China", Public Health Nutrition,
02/2007

Publication

46	cdn.intechopen.com Internet Source	<1 %
47	content.onlinejacc.org Internet Source	<1 %
48	eprints.whiterose.ac.uk Internet Source	<1 %
49	feyz.kaums.ac.ir Internet Source	<1 %
50	jurnal.abulyatama.ac.id Internet Source	<1 %
51	medarticle.top Internet Source	<1 %
52	www.ClinicalTrials.gov Internet Source	<1 %
53	www.dovepress.com Internet Source	<1 %
54	www.nice.org.uk Internet Source	<1 %
55	A S Wierzbicki. "Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort", Heart, 2005 Publication	<1 %

56

Po-Hsun Huang, Ya-Wen Lu, Yi-Lin Tsai, Yen-Wen Wu et al. "2022 Taiwan lipid guidelines for primary prevention", Journal of the Formosan Medical Association, 2022

Publication

<1 %

57

Tran Quang Binh, Pham Tran Phuong, Bui Thi Nhung, Do Dinh Tung. "Metabolic syndrome among a middle-aged population in the Red River Delta region of Vietnam", BMC Endocrine Disorders, 2014

Publication

<1 %

58

Alireza Pishgahi, Rozita Abolhasan, Shahla Danaii, Bahareh Amanifar et al. "Immunological and oxidative stress biomarkers in Ankylosing Spondylitis patients with or without metabolic syndrome", Cytokine, 2020

Publication

<1 %

59

Ho Yin Chung, Jin Xian Huang, Shirley Chiu Wai Chan, Kam Ho Lee, Helen Hoi Lun Tsang, Chak Sing Lau. "Clinical, radiological, and magnetic resonance imaging characteristics of axial spondyloarthritis with late onset", Medicine, 2022

Publication

<1 %

60

Jung, Un, and Myung-Sook Choi. "Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between

<1 %

Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease", International Journal of Molecular Sciences, 2014.

Publication

61

Rikke A. Andreassen, Lars E. Kristensen, Kenneth Egstrup, Xenofon Baraliakos et al. "The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study", Arthritis Research & Therapy, 2019

<1 %

Publication

62

Robert Landewé. "New considerations in the design of clinical trials for spondyloarthritis", Clinical Investigation, 11/2011

<1 %

Publication

63

Shannon Wu, Keren Zhou, Anita Misra-Hebert, James Bena, Sangeeta R. Kashyap. "Impact of Metabolic Syndrome on Severity of COVID-19 Illness", Metabolic Syndrome and Related Disorders, 2022

<1 %

Publication

64

de Moraes, Mariana Teichner, Fernando Henrique Carlos de Souza, Thiago Bitar Moraes de Barros, and Samuel Katsuyuki Shinjo. "An analysis of metabolic syndrome in adult dermatomyositis with a focus on

<1 %

cardiovascular disease", Arthritis Care & Research, 2012.

Publication

Exclude quotes On

Exclude matches Off

Exclude bibliography On

04. Correlation of Radiographic Damage and Metabolic Syndrome in Spondyloarthritis A Cross-Sectional Study

GRADEMARK REPORT

FINAL GRADE

/100

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5
